Home › Multiple Myeloma › Virginia
Multiple Myeloma clinical trials in Virginia
20 studies for Multiple Myeloma are looking for participants at sites in Virginia.
Cities in Virginia
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Gainesville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07391657A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Virginia Commonwealth University - Massey Cancer Center, Richmond
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06500884A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Alexander T. Augusta Military Medical Center, Fort Belvoir
- Virginia Oncology Associates Brock Cancer Center, Norfolk
- Richmond VA Medical Center, Richmond
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05552222A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Charlottesville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07073547Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- VCU Massey Comprehensive Cancer Center, Richmond
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06465316TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Inova Schar Cancer Institute, Fairfax
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT02693535A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Virginia Cancer Specialists - Fairfax /ID# 278716, Fairfax
- Blue Ridge Cancer Care - Roanoke /ID# 278722, Roanoke
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07095452Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Virginia Oncology Associates, Norfolk
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06297226AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT06106945AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Charlottesville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Fairfax
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT07764978A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Virginia Cancer Specialists - Fairfax /ID# 268559, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05650632Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Sovah Health Martinsville, Martinsville
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- and 2 more
RecruitingPhase 3
All ages · All sexes · Updated Jun 10, 2026 · NCT05561387Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- Virginia Oncology Associates, Norfolk
RecruitingPhase 2
Ages 19 and older · All sexes · Updated Jun 4, 2026 · NCT06974786Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Virginia Oncology Associates, Norfolk
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT05243797A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Fairfax
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT06679101Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Virginia Cancer Specialists, Fairfax
- Blue Ridge Cancer Center, Roanoke
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT05972135A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- University of Virginia, Charlottesville
- Virginia Cancer Specialists, Fairfax
- Virginia Oncology Associates, Norfolk
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Mar 24, 2026 · NCT04988555CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Virginia Commonwealth University, Richmond
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT05722418IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- NEXT Oncology Virginia, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 3, 2025 · NCT06119685From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.